Imperial College London
Portrait Picture

Professor Thanos Athanasiou MD PhD MBA FECTS FRCS

Faculty of Medicine, Department of Surgery & Cancer

Professor of Cardiovascular Sciences
 
 
 
//

Contact

 

t.athanasiou

 
 
//

Location

 

1022Queen Elizabeth the Queen Mother Wing (QEQM)St Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Xanthopoulos:2022:10.3390/jcm11205988,
author = {Xanthopoulos, A and Magouliotis, DE and Tryposkiadis, K and Zotos, P-A and Spiliopoulos, K and Athanasiou, T and Giamouzis, G and Skoularigis, J and Starling, RC and Triposkiadis, F},
doi = {10.3390/jcm11205988},
journal = {J Clin Med},
title = {Post-Implant Phosphodiesterase-5 Inhibitors in Patients with Left Ventricular Assist Device: A Systematic Review and Meta-Analysis.},
url = {http://dx.doi.org/10.3390/jcm11205988},
volume = {11},
year = {2022}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Background: Despite the improvement in left ventricular assist device (LVAD) technology and the advent of third-generation LVADs, hemocompatibility-related events remain a significant issue. Therefore, new pharmacological treatments are necessary to optimize patient management and to further reduce hemocompatibility-related events. The purpose of the present systematic review and meta-analysis was to summarize the existing data regarding the safety and efficacy of post-implant phosphodiesterase-5 inhibitors (PDE-5i) on hemocompatibility-related events. Methods: Among the 258 articles in Pubmed, Scopus, and CENTRAL that were retrieved (1990−2022), 15 studies were included in the qualitative synthesis, and 9 studies were included in the quantitative synthesis. The fixed-effects model was used because it is statistically sound for combining a very small number of studies. The primary endpoint of the study was all-cause mortality, whereas the secondary endpoints were ischemic stroke, pump thrombosis, and gastrointestinal bleeding. Results: Mortality was significantly lower in the PDE-5i group vs. the control group (OR: 0.92 [95% CI: 0.85, 0.98]; p = 0.02). The secondary endpoints ischemic stroke (OR: 0.87 [95% CI: 0.78, 0.98]; p = 0.02) and pump thrombosis (OR: 0.90 [95% CI: 0.82, 0.99]; p = 0.04) were also lower in the PDE-5i group. The incidence of gastrointestinal bleeding was significantly higher in patients with LVAD receiving PDE-5i (OR: 1.26 [95% CI: 1.11, 1.44]; p < 0.01). In the overall analysis, the heterogeneity of outcomes was low, except for pump thrombosis. Conclusions: The use of PDE-5i post-implant was associated with lower mortality and thrombotic events but with a higher risk of gastrointestinal bleeding.
AU  - Xanthopoulos,A
AU  - Magouliotis,DE
AU  - Tryposkiadis,K
AU  - Zotos,P-A
AU  - Spiliopoulos,K
AU  - Athanasiou,T
AU  - Giamouzis,G
AU  - Skoularigis,J
AU  - Starling,RC
AU  - Triposkiadis,F
DO  - 10.3390/jcm11205988
PY  - 2022///
SN  - 2077-0383
TI  - Post-Implant Phosphodiesterase-5 Inhibitors in Patients with Left Ventricular Assist Device: A Systematic Review and Meta-Analysis.
T2  - J Clin Med
UR  - http://dx.doi.org/10.3390/jcm11205988
UR  - https://www.ncbi.nlm.nih.gov/pubmed/36294308
VL  - 11
ER  -
Download